CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia Post author: Post published:April 20, 2026 Post category: Continue ReadingCD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Post author: Post published:April 20, 2026 Post category: Continue ReadingCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Post author: Post published:April 20, 2026 Post category: Continue ReadingNonconforming Lisocabtagene Maraleucel Expanded Access Protocol
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) Post author: Post published:April 20, 2026 Post category: Continue ReadingA Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Post author: Post published:April 20, 2026 Post category: Continue ReadingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Post author: Post published:April 20, 2026 Post category: Continue ReadingLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingExpanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
